Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA by Bartels, A. L. et al.
PARKINSON’S DISEASE AND ALLIED CONDITIONS - ORIGINAL ARTICLE
Decreased blood–brain barrier P-glycoprotein function
in the progression of Parkinson’s disease, PSP and MSA
A. L. Bartels Æ A. T. M. Willemsen Æ R. Kortekaas Æ
B. M. de Jong Æ R. de Vries Æ O. de Klerk Æ
J. C. H. van Oostrom Æ A. Portman Æ K. L. Leenders
Received: 22 November 2007/Accepted: 25 January 2008/Published online: 12 February 2008
 The Author(s) 2008
Abstract Decreased blood–brain barrier (BBB) efﬂux
function of the P-glycoprotein (P-gp) transport system
could facilitate the accumulation of toxic compounds in the
brain, increasing the risk of neurodegenerative pathology
such as Parkinson’s disease (PD). This study investigated
in vivo BBB P-gp function in patients with parkinsonian
neurodegenerative syndromes, using [
11C]-verapamil PET
in PD, PSP and MSA patients. Regional differences in
distribution volume were studied using SPM with higher
uptake interpreted as reduced P-gp function. Advanced PD
patients and PSP patients had increased [
11C]-verapamil
uptake in frontal white matter regions compared to con-
trols; while de novo PD patients showed lower uptake in
midbrain and frontal regions. PSP and MSA patients had
increased uptake in the basal ganglia. Decreased BBB P-gp
function seems a late event in neurodegenerative disorders,
and could enhance continuous neurodegeneration. Lower
[
11C]-verapamil uptake in midbrain and frontal regions of
de novo PD patients could indicate a regional up-regulation
of P-gp function.
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Introduction
The causes of neurodegenerative brain diseases are
unknown. Also the factors that result in continuous neu-
rodegeneration in these diseases are not understood.
Genetic susceptibility and exposure to neurotoxins are
contributors to brain tissue malfunction and neuronal cell
loss. Environmental toxins inﬂuence PD onset (Rajput
2001) and are also suggested to be involved in atypical
parkinsonian syndromes (Caparros-Lefebvre and Lees
2005) and progressive supranuclear palsy (PSP) (Davis
et al. 1988). Furthermore, the age-related neurodegenera-
tive disorders are commonly characterised by the
accumulation of insoluble neurotoxic ubiquinated proteins
(Johnson 2000). The neurotoxin hypothesis states that
detoxiﬁcation enzymes can inﬂuence susceptibility to PD,
but recently another mechanism has also been recognised
as important for detoxiﬁcation of the brain. Proteins
that are involved in cellular efﬂux prevent penetration
into the brain by various potentially toxic compounds or
their accumulation. They include P-glycoprotein (P-gp)
(Cordon-Cardo et al. 1989) and multidrug resistance
associated protein (MRP). At the blood–brain barrier
(BBB), P-gp is expressed in a high concentration at the
luminal side of the brain vascular endothelium (Demeule
et al. 2001) and functions as an efﬂux pump by
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P-gp in the endothelial cells of the choroid plexus has a
transport direction towards the CSF (de Lange 2004). P-gp
could thus play a role in brain detoxiﬁcation via different
routes.
The P-gp transporter is associated with the multidrug
resistance gene (MDR1). Interestingly, a signiﬁcant asso-
ciation was found between parkinsonian patients exposed
to pesticides and C3435T polymorphism of the MDR1
gene, related to lower P-gp function (Drozdzik et al. 2003;
Furuno et al. 2002). Thus the mutation of the MDR1 gene
with diminished P-gp function increases the vulnerability
to the damaging effects of pesticides. It is assumed that
neurotoxic substances such as certain pesticides are sub-
strates of P-gp (Bain and LeBlanc 1996) and CNS exposure
to such agents may continue to cause neurodegenerative
diseases.
In a pilot study (Kortekaas et al. 2005), impaired BBB P-
gp transport was found in the midbrain of ﬁve PD patients
compared to ﬁve healthy control subjects, measured with
[
11C]-verapamil PET, pointing to a role of P-gp in the brain
to prevent accumulation of toxic substances causing PD
neurodegeneration. This ﬁnding, however, could not be
replicated in a study that measured P-gp function with
[
11C]-(R)-verapamil PET in ten early stage PD patients
compared to healthy controls (Bartels et al. 2007).
Decreased expression of P-gp in BBB vasculature has
been found in other neurodegenerative diseases, like
Alzheimer’s disease (AD) (Vogelgesang et al. 2001) and
Creutzfeldt–Jakob disease (CJD) (Vogelgesang et al.
2006a). In AD, P-gp up-regulation in early pathogenesis
was suggested as a compensatory mechanism to increase
the clearance of harmful proteins, while at later disease
stages P-gp expression was lost (Vogelgesang et al.
2001).
We hypothesize that P-gp-mediated transport out of the
brain is involved in clearance of harmful substances and
dysfunction of this system also occurs in late stage par-
kinsonian neurodegeneration. In the present study, we
performed [
11C]-verapamil-PET brain imaging of new
groups of de novo PD patients, PD patients in more
advanced disease stages, progressive supranuclear palsy
(PSP), and multisystem atrophy (MSA) patients and a
healthy control group, to study regional BBB P-gp function
in patients with different parkinsonian pathology. PET with
[
11C]-verapamil has been shown to be an appropriate
methodology for the in vivo assessment of the functional
P-gp status in human BBB (Hendrikse et al. 1999). The
distribution volume (DV) of the P-gp substrate verapamil
can be taken as a measure of P-gp efﬂux function, higher
[
11C]-verapamil uptake meaning less P-gp efﬂux function.
The effect of the MDR1 gene polymorphism was addi-
tionally investigated.
Materials and methods
Patients were selected from the Movement Disorders
Clinic of the University Medical Centre Groningen;
healthy volunteers were asked to participate by adver-
tisement. The study was approved by the Medical Ethics
Committee of the University Medical Centre Groningen
and all subjects gave their informed consent. PD was
diagnosed according to the criteria of Gelb et al. (1999).
Ten de novo PD patients (diagnosed in the past year and
without PD medication), and ten PD patients in more
advanced disease stage (Hoehn and Yahr stages 2–3)
participated in the study (Table 1). Furthermore, ﬁve
patients with PSP and four patients with MSA, compliant
with the criteria for PSP or MSA according to the
NINDS-SPSP international workshop (Litvan et al. 1996)
and the consensus statement for the diagnosis of MSA
(Gilman et al, 1999) were included. Nine healthy age-
matched subjects, who did not use medication, partici-
pated as controls. Patients did not use known P-gp
modulating agents [(cardiovascular drugs, antimalarial
drugs, cyclosporine A, phenothiazines, hormones (e.g.,
tamoxifen)] and certain antibiotics such as cefoperazone,
ceftriaxone, and erythromycine [see for a detailed list
(Hendrikse et al. 2001)]. T1 weighted MRI scans were
performed on all subjects and did not show abnormalities
or signiﬁcant atrophy of cortical regions.
Table 1 Patient characteristics
Diagnosis (N) Mean age Disease duration UPDRS III Medication
PD (10) 63 SD 8 5 years SD 2 21 SD 7 (‘‘on’’state) Levodopa + dopamine-agonist
(ropinirole or pramipexole or pergolide)
PD de novo (10) 66 SD 9 \1 year 19 SD 8 x
PSP (5) 63 SD 8 3 years SD 2 20 SD 8 Amantadine (2 patients)
MSA (4) 59 SD 11 3 years SD 2 27 SD 3 Levodopa (2 patients)
Controls (10) 59 SD 10 None 0 None
Mean values for the groups are given with standard deviations (SD)
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11C]-verapamil was synthesised as described before
(Wegman et al. 2002). PET scans were performed with an
ECAT EXACT HR + positron camera (Siemens/CTI,
Knoxville, TN). After cannulation of the radial artery, all
subjects underwent 1 h dynamic PET scanning consisting
of 21 frames after injection of [
11C]-verapamil (200–
400 MBq). Serial arterial blood sampling to deﬁne the
input function for
11[C]-verapamil was done using a com-
puterised sampling programme; six remaining samples
were drawn manually. These samples (collected at intervals
of 10 min) were processed by high liquid chromatography
to measure the fraction of unmetabolised parent compound.
In this way the contribution to the total signal can be cal-
culated. PET data were reconstructed to a 128 9 128 9 63
matrix with a plane separation of 2.425 and a bin size of
2.250 mm.
For anatomical demarcation, the frames 12–21 of the
dynamic [
11C]-verapamil scans were summated using
Clinical Application Programming Package (CAPP;
Siemens, Erlangen, Germany). On this summated image,
CAPP regions of interest (ROIs) were manually drawn over
the midbrain and whole brain to calculate distribution
volume (DV) in the ROIs. Using Matlab (The Mathworks
Inc., Natick, USA) and a linearization according to Logan
(2000), starting at t = 5 min, DV images were constructed
from the
11[C]-verapamil scans, which was done for the
whole brain ROI as well as pixelwise to obtain parametric
DV images. Logan analysis is a graphical method of
analysis, applicable to ligands that bind reversibly to
receptors or enzymes, calculating the DV for dynamic PET
data before steady state is actually reached. For comparison
of regional differences between the groups, parametric DV
images were analysed using statistical Parametric Mapping
(Friston et al. 1991) (SPM99, Wellcome Department of
Cognitive Neurology, London, UK). SPM99 instead of the
latest SPM version was used to compare the results with
those of the pilot study (Kortekaas et al. 2005). Individual
DV images were spatially normalised to the [
11C]-verap-
amil DV template that was constructed in the pilot study.
After spatial smoothing by convolution with a Gaussian
kernel of 20 mm, a two-sample t test was done. To visu-
alize the statistical parametric maps, the threshold was set
to P\0.001 uncorrected. Because higher variation in DV
between individuals may render smaller differences
between the groups statistically insigniﬁcant in SPM, t tests
were repeated after global calculation of the DV images
to 100 in SPM. We also used this SPM analysis method
to compare our results with the previous pilot study
(Kortekaas et al. 2005).
Fromeachsubject10 mlbloodwascollectedinanEDTA
coated vial for determination of MDR1 C3435T polymor-
phism on exon 26. A polymerase chain reaction (PCR)-
based restriction fragment length polymorphism assay was
performed with the primers MDR1F 50-TGCTGGTCC
TGAAGTTGATCTGTAAC-30 andMDR1R50-ACATTAG
GCAGTGACTCGATGAAGGCA-30. PCR was carried out
with an initial denaturation of 12 min at 95C followed by
30 cycles of denaturation at 94C for 1 min, primer
annealing for 1 min at 60C, and 1 min extension at 70C.
When the mutation was present (3435T), digesting of the
248 bp PCR-product produced the 172-, 60 bp and 16-bp
fragments. The digested PCR products were analysed on a
2%agarosegelwithethidiumbromidestaining.Wholebrain
verapamilDVofallsubjectswasplottedagainsttheC3435T
polymorphism (CC, CT and TT genotypes), and correlation
coefﬁcient of genotype with DV was calculated in all sub-
jects and in the separate groups.
Results
[
11C]-verapamil uptake was high in the pituitary, ventricles
and skin, moderate in grey matter and low in white matter
and bone. Visual inspection of the scans revealed no
obvious differences between the groups. The Logan anal-
ysis provides the DV of a tracer, and is deﬁned by a ratio
between the inﬂux of the tracer K1 and the efﬂux out of the
brain K2, of which the latter reﬂects the efﬂux function of
P-gp. The inﬂux K1 of [
11C]-verapamil was of the same
magnitude in all groups, which conﬁrms that differences in
DV reﬂect differences in P-gp efﬂux function. Mean DV in
the more advanced PD group was 0.56 (SD 0,12), de novo
PD showed 0.50 (SD 0,08), PSP 0.66 (SD 0,05), MSA 0.66
(SD 0,07) and controls 0.59 (SD 0,13). K1 in the PD group
gave 0.037 (SD 0,013), PSP 0.038 (SD 0,005), MSA 0.036
(SD 0,006) and controls 0.036 (SD 0,006). Differences in
DV between the groups were not statistically signiﬁcant.
Pixel by pixel t test (P\0.001 uncorrected) in SPM did
not show increased midbrain [
11C]-verapamil uptake in
either of the PD groups as compared to the control group.
The advanced PD group showed signiﬁcantly increased
11[C]-verapamil uptake in frontal white matter regions
compared to controls (SPM coordinates 34, 30, 26 and
-16, 48, 12, near grey matter Brodmann areas 9 and 10, P
corrected at cluster level 0.000, Fig. 1); a cluster with
decreased uptake was seen in the cerebellar tonsils (max-
imum effect at coordinates 40, -54, -46). The de novo PD
group had lower uptake in brainstem and cerebellar tonsils
(brainstem coordinates 2, -26, -26 with P corrected at
cluster level 0.000, Fig. 2) compared to the control group
and did not show clusters with higher uptake. Plots of the
local SPM responses showed a considerable separation of
the groups, although there are some overlapping cases,
where the PD groups show larger variation in local
response values. Comparison of de novo and advanced PD
groups revealed a cluster of pixels reﬂecting higher uptake
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(coordinates 4, 28, -6) and in the caudate head (coordi-
nates 14, 14, 2 with P corrected at cluster level 0.01).
In the PSP group, signiﬁcantly increased uptake was
seen in basal ganglia regions (maximum effect in lentiform
nucleus, coordinates 26, -10, 6 with P corrected at cluster
level 0.06, Fig. 3). When plotting the effect, one PSP
patient did not show higher uptake compared to the healthy
controls (Fig. 3). Notably, this was also the patient with
shortest disease duration (\1 year) and only mild parkin-
sonian symptoms (UPDRS motor part score 12). The PSP
group had also increased uptake in frontal regions com-
pared both to controls and the advanced PD group, but this
did not reach signiﬁcance and plotting the effect showed
Fig. 1 a SPM t test on MRI overlay showing P\0.001. Increased
[
11C]-verapamil uptake in the frontal lobe in advanced PD patients
compared to healthy controls; SPM coordinates 34, 30, 26 and -16,
48, 12 (Brodmann areas 9 and 10) with P corrected at cluster level
0.000. b Plot of the frontal effect (PD patients scan number 1–10 and
controls 11–20) shows little overlap
Fig. 2 a de novo PD patients showed lower brainstem [
11C]-
verapamil uptake in the brainstem compared to controls, P\0.001;
SPM coordinates 2, -26, -26 with P corrected at cluster level 0.000.
b Plot of the brainstem effect shows more variation in PD de novo
values (scan number 1–10) with some overlap with the control group
(scan number 11–20)
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not show signiﬁcant differences compared to controls,
however after lowering the threshold to P\0.01, also
increased uptake in basal ganglia regions was seen with
P corrected at cluster level 0.98 and uncorrected P at 0.056
in putamen (28, -6, -2). Plot of the SPM effect showed
more variance between the MSA patients with one patient
in the control range. This patient had lower disease severity
compared to the other MSA patients, with 2 years disease
duration and UPDRS motor score 24.
All results did not remain statistically signiﬁcant after
correction for multiple comparisons in SPM (FDR cor-
rection with level of signiﬁcance set at P\0. 05) possibly
due to the higher inter-subject variation. T-tests in SPM
were repeated after global calculation of the DV images to
100, which showed comparable results and did not reveal
additional foci with relative DV differences between the
groups.
The frequencies of the determined MDR1 polymor-
phism in our study group did not differ from the
frequencies seen in the general population (Tan et al.
2004). Furthermore, C3435T genotypes did not signiﬁ-
cantly correlate with the differences in [
11C]-verapamil DV
in the brain in all groups.
We compared [
11C]-verapamil PET data of the present
study with data of the previously published pilot study that
was performed by our group. All subjects showed com-
parable K1 and DV values. Mean injected dose was lower
in the pilot study with 111 MBq given as lowest dose; for a
better signal-to-noise ratio, the cut-off dose for the current
study was set at 200 MBq. The previous pilot control group
showed relatively lower midbrain uptake compared to the
nine control subjects of this study, which, however, only
was shown in SPM after global calculation of the mean DV
to 100. Neither group used medication nor was there a
signiﬁcant age difference between both the control groups,
although the pilot group had one outlier of 86 years. We
could not demonstrate a deﬁnite methodological explana-
tion for the midbrain effect in the pilot control subjects.
However in our opinion, global calculation of the mean
may have affected the results in the midbrain area, which is
a small region with a low uptake signal and is thereby
prone to artefacts. Finally, because of the lower injected
tracer dose, data of the previous pilot study were not fur-
ther used for the present study.
Discussion
The results of this study do not support the idea of a
primary dysfunctional BBB P-glycoprotein efﬂux system
in the pathogenesis of Parkinson’s disease, but ﬁnds
decreased P-gp function at later disease stages. This is in
line with a most recent study that measured BBB P-gp
function in mostly early stage PD patients using [
11C]-
(R)-verapamil, where higher variance in tracer uptake
was seen in several regions in the PD group, but no
signiﬁcant decreased P-gp function was found (Bartels
et al. 2007).
Fig. 3 a PSP patients showed higher [11C]-verapamil uptake in
lentiform nucleus and putamen compared to controls, P\0.001;
SPM coordinates 26, -10, 6 with P corrected at cluster level 0.06.
b Plot of the basal ganglia effect shows higher values in four of the
ﬁve PSP patients (scan number 1–5). PSP patient number 5 had
shortest disease duration (\1 year)
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diminished P-gp function relative to normal controls and de
novo PD patients. Regional frontal decreases in both
advanced PD and advanced PSP possibly reﬂects the
affected frontostriatal neuronal projections with frontal
dysfunction in these disease stages (Green et al. 2002). The
increased uptake lies in the white matter regions rather than
the cortex. In general, white matter shows similar [
11C]-
verapamil uptake as grey matter. Involvement of white
matter regions and vasculature in neurodegenerative dis-
orders that can be seen as ‘‘proteinopathies’’, involving
accumulation of misfolded proteins, is a topic of important
discussion. It was shown in vitro that b-amyloid is trans-
ported by P-gp (Kuhnke et al. 2007; Lam et al. 2001;
Vogelgesang et al. 2006b). Interestingly, the deposition of
Ab1–40 in cerebral amyloid angiopathy (CAA), which is
found in around 90% of AD patients, is predominantly
found in the penetrating arterioles that supply the peri-
ventricular white matter (Lee and Markus 2006). Another
study associated the failure of interstitial ﬂuid drainage
from the white matter in AD with the deposition of Ab in
the perivascular ﬂuid drainage pathways (Roher et al.
2003). Thus, decreased P-gp function in white matter
regions may inﬂuence protein removal and accumulation at
sites more distant from the white matter. Furthermore, it is
suggested that Lewy Body-related pathology initially
involves the neuronal perikarya, dendrites, and axons, with
abundantly present ‘‘Lewy axons’’ in the limbic subcortical
white matter (Saito et al. 2003). These authors also ﬁnd that
impairment of axonal transport and synaptic transmission
leads to the formation of Lewy Bodies, a hallmark of
functional disturbance long before neuronal cell death.
White matter P-gp dysfunction might also inﬂuence
removal of toxic substances such as pesticides, which could
cause harm to distant sites of the white matter after alter-
ations of axonal transport, leading to ‘‘dying-back’’
patterns of neurodegeneration (Morﬁni et al. 2007).
In PD, greater disease severity and a more rapid neu-
rodegenerative process have been associated with white
matter hyperintensities (Piccini et al. 1995). However,
although speciﬁc methodology or rating scales were not
used to assess white matter pathology on the MRI’s in this
study, we could not detect any visually apparent white
matter hyperintensities in any subject.
Both de novo and more advanced PD patients showed
lower [
11C]-verapamil uptake in the cerebellum. The cer-
ebellum is closely linked to midbrain nuclei, but is by itself
not affected with progression of PD pathology (Braak and
Braak 2000). Possibly, P-gp function in these regions is
increased in PD, but does not deteriorate in later stages, as
these regions are not vulnerable to PD pathology. On the
other hand, in MSA cerebellar degeneration can be part
of the disease spectrum. We did not ﬁnd changed P-gp
function in the cerebellum in the MSA patients. However,
the MSA patients in this study did not show symptoms of
cerebellar dysfunction and MRI scans did not show cere-
bellar atrophy.
PSP and MSA patients showed basal ganglia regions
with increased [
11C]-verapamil uptake, pointing at
decreased P-gp function in regions with neuropathological
features in these disorders. Brain atrophic changes are not
likely to play a role in these results, because MRI scans did
not show overt atrophy in these regions. Moreover, tissue
loss would lead to decreased [
11C]-verapamil uptake in
these regions. PSP patients also showed decreased P-gp
function in frontal regions. Although this result was not
signiﬁcant, plotting this effect showed higher variation
between the PSP patients with one PSP patient in early
disease stage who showed values overlapping with the
controls (Fig. 3). These results may possibly point at
regionally decreased P-gp function with advancing disease
stage.
Regionally decreased P-gp function could thus occur not
only in more advanced PD, but may also play a role in
other neurodegenerative diseases with parkinsonism, and
likely plays a role in advancing neurodegenerative pro-
cesses in general. It has been argued that decreased
cerebrovascular P-gp impairs the ability of the brain to
expel excess proteins, and that the resulting accumulation
of protein in cells could overwhelm cellular ubiquitin-
proteasomal degradation (Vogelgesang et al. 2006a). P-gp
was even found to interact actively with the proteasome
complex, and a role for P-gp in the transport of protea-
some-derived peptides was suggested (Begley et al. 2005).
Loss of P-gp function may possibly also lead to increased
accumulation of insoluble a-synuclein with ongoing neu-
rodegeneration in PD. P-gp dysfunction in late disease
stage may also contribute to neuronal damage due to
increased accumulation of toxins. It is known that envi-
ronmental factors causing damage, such as pesticides, are
closely linked to mechanisms underlying the formation of
a-synuclein pathology and PD-like neurodegeneration
(Norris et al. 2007). Furthermore, it is recognised that the
prevalence of dementia is higher in PD patients than in age-
matched controls, which often is found to be deﬁned by AD
pathology in conjunction to the Lewy bodies (Burn 2006).
Decreased P-gp function to expel proteins in advanced PD
could also play a role in the co-existence of a-synuclein
and b-amyloid in PD with dementia (PDD), a patient group
that was not investigated in the present study.
In the study presented here, de novo PD patients showed
lower [
11C]-verapamil uptake compared to normal controls
in the brainstem, which may indicate a regional up-regu-
lation of P-gp function in early stage PD. The brainstem
regions lies posterior to the pons, comprising the locus
coeruleus and lying slightly superior to the dorsal motor
1006 J Neural Transm (2008) 115:1001–1009
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pathology (Del et al. 2002), containing projection neurons
of the intermediate reticular zone, coeruleus–subcoeruleus
complex and caudal raphe nuclei.
A limitation of the methods, using [
11C]-verapamil
uptake as a measure of P-gp efﬂux function, is the low
uptake signals of this tracer in the normal condition, as it is
removed by P-gp. Intersubject variation in tracer uptake
can be substantial, whereby small regional effects may be
overlooked in the statistical comparison. On the other hand,
global calculation can be applied to investigate regional
patterns within disease groups rather than absolute P-gp
measures. This should be applied with care, as small
regions with low uptake signals may be prone to artefactual
changes. In the case of the present study, the brainstem
effect was also seen without proportional scaling in SPM,
and is therefore more likely a signiﬁcant result.
Initial up-regulation of P-gp expression or increase of
P-gp function in reaction to neuronal damage may be
associated with a neuroinﬂammatory process in Parkin-
son’s disease. In PD as well as in other neurodegenerative
diseases, extensive microglia activation, the key event in
neuroinﬂammation, is seen (Gerhard et al. 2001; Mcgeer
and Mcgeer 1998, 2004). Microglia themselves express
P-gp, which increases upon microglia activation (Langford
et al. 2004). Several factors that are involved in inﬂam-
matory processes, like TNF-a, IL-6 and nitric oxide (NO)
may increase P-gp function (Fernandez et al. 2004; Mcrae
et al. 2003). Furthermore, Tan et al. (2002) showed that
exposure of BBB endothelial cells to activated T-lympho-
cytes induced endothelial cell death, whereas P-gp
expression and function was increased in surviving cells.
The authors conclude that P-gp could play a regulatory role
in promoting survival of cerebral endothelial cells and
maintenance of BBB function. In conclusion, neuronal
damage with a subsequent neuroinﬂammatory reaction
could, by activating the P-gp system promote the clearance
of the brain of potentially toxic compounds.
An initially compensatory mechanism with up-regu-
lation of P-gp expression has also been suggested in the
early pathogenesis of Alzheimer’s disease (AD). At later
disease stages, P-gp expression in the capillaries was
lost. P-gp in the brain could thus form a compensatory
mechanism to increase clearance of neurotoxic sub-
stances that play a role in neurodegenerative diseases. A
similar role for P-gp was also suggested in Creutzfeldt–
Jakob Disease (CJD), where decreased P-gp expression
was suggested to facilitate the accumulation of PrP
Sc
prions (Vogelgesang et al. 2006a). Whether P-gp also
transports a-synuclein, a major constituent of Lewy
bodies that causes neurodegeneration in PD when
aggregated, has so far not been investigated. Further-
more, it is known that P-gp contributes to the cellular
efﬂux of some pesticides (Bain and LeBlanc 1996) and
environmental toxins inﬂuence PD onset (Rajput, 2001).
However, decreased P-gp function was not seen in de
novo PD patients, indicating that impaired BBB P-gp
efﬂux function does not play a primary role in the ini-
tiation of pathology in idiopathic PD.
The ﬁndings of our study could have implications in the
therapeutic options in PD and other proteopathies. P-gp
activity can be modulated by a variety of substances, but
most studies focus on P-gp inhibition, e.g., in the preven-
tion of multidrug resistance in oncological treatments (Tan
et al. 2000). However, P-gp activity can also be up regu-
lated, for example by St Johns worth or rifampicin (Fromm
2000; Hennessy et al. 2002). Selectively increasing P-gp
mediated BBB efﬂux function would provide a possible
novel therapeutic means to prevent further accumulation of
insoluble toxic compounds or proteins leading to ongoing
neurodegeneration.
We conclude that cerebrovascular P-gp function is
regionally decreased with advanced stages in several par-
kinsonian neurodegenerative diseases, implying decreased
regulatory and protective function of the BBB with ongo-
ing neurodegeneration.
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